Welcome to Paid Research Studies




  • Condition:   Hearing Loss
    Interventions:   Other: Current Primary Care Referral Process;   Other: Telemedicine Referral Process
    Sponsors:   Norton Sound Health Corporation;   Duke University;   Johns Hopkins University;   Patient-Centered Outcomes Research Institute
    Recruiting

  • Condition:   Colon Cancer
    Interventions:   Dietary Supplement: 70g of fully digestible starch amylopectin corn starch;   Dietary Supplement: Resistant starch
    Sponsors:   University of Pittsburgh;   Alaska Native Tribal Health Consortium
    Not yet recruiting

  • Condition:   Breast Carcinoma
    Interventions:   Other: Health Education Program;   Other: Weight Loss Intervention
    Sponsors:   Alliance for Clinical Trials in Oncology;   National Cancer Institute (NCI);   Division of Cancer Control;   NIH Biomarker, Imaging and Quality of Life Studies Funding Program (BIQSFP)
    Recruiting

  • Condition:   Obesity
    Interventions:   Other: Optifast;   Other: Food-Based
    Sponsors:   Nestlé;   TKL Research, Inc.
    Active, not recruiting

  • Conditions:   Nicotine Dependence;   Pregnancy
    Interventions:   Behavioral: Biomarker feedback (phone based smoking cessation counseling);   Behavioral: Control condition (phone based smoking cessation counseling)
    Sponsors:   Mayo Clinic;   Alaska Native Tribal Health Consortium;   University of California, San Francisco;   University of Minnesota - Clinical and Translational Science Institute
    Active, not recruiting

  • Conditions:   Diffuse Large B-Cell Lymphoma Activated B-Cell Type;   Diffuse Large B-Cell Lymphoma, Not Otherwise Specified;   High Grade B-Cell Lymphoma, Not Otherwise Specified;   Recurrent Diffuse Large B-Cell Lymphoma;   Refractory Diffuse Large B-Cell Lymphoma
    Interventions:   Procedure: Autologous Bone Marrow Transplantation;   Procedure: Autologous Hematopoietic Stem Cell Transplantation;   Drug: Carmustine;   Drug: Cyclophosphamide;   Drug: Cytarabine;   Drug: Etoposide;   Drug: Ibrutinib;   Other: Laboratory Biomarker Analysis;   Drug: Melphalan;   Other: Placebo
    Sponsor:   National Cancer Institute (NCI)
    Recruiting

  • Condition:   CIED Related Infection
    Intervention:   Device: TYRX Absorbable Antibacterial Envelope
    Sponsors:   Medtronic Cardiac Rhythm and Heart Failure;   The Cleveland Clinic
    Active, not recruiting

  • Condition:   Nicotine Dependence
    Intervention:   Behavioral: Community level intervention
    Sponsors:   Mayo Clinic;   Yukon Kuskokwim Health Corporation;   University of Minnesota - Clinical and Translational Science Institute;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Sensorineural Hearing Loss;   Long QT Syndrome
    Intervention:  
    Sponsor:   Mednax Center for Research, Education and Quality
    Recruiting

  • Condition:   Cardiovascular Disease
    Interventions:   Drug: bococizumab (PF-04950615);   Drug: Placebo
    Sponsor:   Pfizer
    Terminated

  • Condition:   Cardiovascular Disease
    Interventions:   Drug: bococizumab (PF-04950615);   Drug: Placebo
    Sponsor:   Pfizer
    Terminated

  • Conditions:   Fallopian Tube Clear Cell Adenocarcinoma;   Fallopian Tube Endometrioid Adenocarcinoma;   Fallopian Tube Mucinous Adenocarcinoma;   Fallopian Tube Serous Adenocarcinoma;   Fallopian Tube Transitional Cell Carcinoma;   Malignant Ovarian Brenner Tumor;   Ovarian Clear Cell Adenocarcinoma;   Ovarian Endometrioid Adenocarcinoma;   Ovarian Mucinous Adenocarcinoma;   Ovarian Seromucinous Carcinoma;   Ovarian Serous Adenocarcinoma;   Ovarian Transitional Cell Carcinoma;   Primary Peritoneal Serous Adenocarcinoma;   Stage IIA Fallopian Tube Cancer;   Stage IIA Ovarian Cancer;   Stage IIB Fallopian Tube Cancer;   Stage IIB Ovarian Cancer;   Stage IIC Fallopian Tube Cancer;   Stage IIC Ovarian Cancer;   Stage IIIA Fallopian Tube Cancer;   Stage IIIA Ovarian Cancer;   Stage IIIA Primary Peritoneal Cancer;   Stage IIIB Fallopian Tube Cancer;   Stage IIIB Ovarian Cancer;   Stage IIIB Primary Peritoneal Cancer;   Stage IIIC Fallopian Tube Cancer;   Stage IIIC Ovarian Cancer;   Stage IIIC Primary Peritoneal Cancer;   Stage IV Fallopian Tube Cancer;   Stage IV Ovarian Cancer;   Stage IV Primary Peritoneal Cancer;   Undifferentiated Fallopian Tube Carcinoma;   Undifferentiated Ovarian Carcinoma
    Interventions:   Behavioral: Behavioral Dietary Intervention;   Behavioral: Compliance Monitoring;   Other: Counseling;   Other: Educational Intervention;   Behavioral: Exercise Intervention;   Other: Laboratory Biomarker Analysis;   Other: Quality-of-Life Assessment;   Other: Questionnaire Administration
    Sponsors:   Gynecologic Oncology Group;   National Cancer Institute (NCI)
    Recruiting

  • Condition:   Child Abuse
    Intervention:   Behavioral: Home Visiting
    Sponsors:   Johns Hopkins University;   State of Alaska Department of Health and Social Services
    Completed

  • Condition:   Breast Cancer
    Intervention:   Drug: exemestane
    Sponsors:   NCIC Clinical Trials Group;   Grupo Espanol de Investigacion del Cancer de Mama;   UNICANCER
    Active, not recruiting